Search
Displaying 571–580 of 684 for “retinal diseases”
-
Research News
Microperimetry, which measures retinal sensitivity in the macular region, shows promise as outcome measure
-
Interim Results Released for USH2A RNA Therapy Clinical Trial
Research NewsSuggestions of efficacy observed in 25 percent of participants receiving the treatment
-
Including the Foundation in your will or trust provides an opportunity to give a larger gift than you may be able to give out of your current assets. By leaving a gift to the Foundation, you can help fight blinding diseases today and for the future.
By leaving a lasting gift, you’re helping the Foundation while retaining the full use of your assets to provide for today’s needs.
-
Simple Ways to Leave Your Legacy
Many people who don’t have the resources to make a significant gift during their lifetime choose to leave a meaningful gift in their will. By leaving a gift to the Foundation, you will provide vital support for the research that will soon find an end to vision loss. You can leave a legacy of sight.
-
Families and Scientists Meet to Discuss Therapy Development for People with RDH12 Mutations
Research NewsProof-of-concept for RDH12 gene therapy demonstrated in mouse model
-
FDA Authorizes Stem Cell Clinical Trial for RP in Los Angeles
Research NewsPhase 1/2a human study will evaluate neural progenitors for preserving vision
-
Join a growing movement of changemakers who are transforming passion into purpose and turning everyday moments into life-changing impact. When you fundraise for the Foundation Fighting Blindness, you accelerate the science that saves sight—for millions.
-
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Research NewsUnlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.
-
Acucela Enrolling Patients in Phase 3 Trial for Stargardt Disease Treatment
Research NewsThe Seattle biotech Acucela is now enrolling participants in its Phase 3 clinical trial for emixustat hydrochloride, an emerging oral drug for slowing vision loss in people with Stargardt disease, an inherited form of a macular degeneration.
-
Recording Available for Achromatopsia Teleconference Hosted by AGTC, Foundation, and Achroma Corp
Research NewsApplied Genetic Technologies Corporation (AGTC), Achroma Corp, and the Foundation Fighting Blindness hosted a one-hour teleconference on the condition. The call highlighted the difficulties patients have in getting a diagnosis for achromatopsia, the importance of genetic testing, and gene therapy clinical trials underway.
